Acorda Therapeutics Inc. (ACOR) announced Tuesday morning that it has received a Refusal to File letter from the FDA regarding its New Drug Application for INBRIJA, a treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa/levodopa regimen.
from RTT - Before the Bell http://ift.tt/2xM5HXt
via IFTTT
No comments:
Post a Comment